Skip to main content
Fig. 3 | Journal of Neuroinflammation

Fig. 3

From: N-acetylglucosamine inhibits inflammation and neurodegeneration markers in multiple sclerosis: a mechanistic trial

Fig. 3

Change in serum cytokine levels with oral GlcNAc therapy. A–P Averaged cytokine levels before (visits 1–4), during (visits 5–8), and after (visits 9–11) GlcNAc treatment individually (A,C,E,G,I,K,M,O) or combined (B, D, F, H, J, L, N, P) as measured by sandwich ELISA. Only cytokine levels above the LLOQ were included in analysis. Error bars represent SEM. P value by linear mixed models (one-tailed) using all subjects who completed the study

Back to article page